BTIG maintains Buy rating on Avalo Therapeutics, $10 price target

BTIG kept its Buy rating on Avalo Therapeutics with a $10.00 price target, suggesting a 34.2% upside from the Oct 22 close. The firm cited strong Phase 2 trial results for lead asset Abdakibart, favorable safety profile, and market opportunity in hidradenitis suppurativa.

Original reporting
Published Oct 23, 2026, 9:41 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 9:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
BTIG maintains Buy rating on Avalo Therapeutics, $10 price target — source image
Decision brief

The 30-second read

Med
01

Why it matters

The analyst's upgrade and $10 target suggest a material re‑rating that could move the stock.

02

Market read

New analyst rating provides a fresh catalyst for AVXL, likely prompting short‑term buying.

03

What to watch

Potential competition and reimbursement uncertainty could limit upside.

Relevance 7/10Novelty 7/10Timing: today

Background

Avalo Therapeutics is a micro‑cap biotech developing Abdakibart for hidradenitis suppurativa.

Market effects

May lift sentiment for other hidradenitis suppurativa biotech peers.

Limited to US biotech sector.

Low, confined to niche therapeutic area.

Counterpoint

The Phase 2 data may not translate to later stages; target could be optimistic.

Key entities

  • Avalo Therapeutics

    Biotech firm developing Abdakibart.

  • BTIG

    Equity research firm issuing the Buy rating.

Related articles

$AVTXMed

Avalo Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Updates

Avalo Therapeutics, Inc. (AVTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Avalo Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Updates • Advancing abdakibart toward a registrational Phase 3 program in hidradenitis suppurativa, with initiation planned for the first half of 2027 • Advancing AVTX-010, a next-gen

$AVTXMedAI 8/10

AVTX: Advancing anti-IL-1 beta therapy to phase III for HS, expanding indications, and securing strong financial support

Avalo Therapeutics (AVTX) is advancing its anti-IL-1 beta antibody, abdakibart, to phase III trials for hidradenitis suppurativa (HS) after positive phase II results. The company plans to expand indications in dermatology and rheumatology, develop a long-acting version, and secure financial support. The strategy includes differentiated dosing and device approaches.